restrictions on the extent to which a CDC-funded awardee can participate in or implement environmental changes within their respective communities. (See Section: Use of Funds.)

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock Number 017–001–00474–0), or Healthy People 2000 (Summary Report, Stock Number 017–001–00473–1), referenced in the **Introduction** through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325; telephone (202) 512–1800.

Dated: April 17, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–10788 Filed 4–22–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0531]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Performance Standard for Electrode Lead Wires and Patient Cables: Petitions for Exemptions and Variances'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 21, 1998 (63 FR 3141), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0367. The approval expires on April 30, 2001.

Dated: April 16, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–10778 Filed 4–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0485]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Shipment of a Blood Product Prior to Completion of Testing for Hepatitis B Surface Antigen (HbsAg), and Shipment of Blood Products Known Reactive for HbsAg'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: JonnaLynn P. Capezzuto, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 19, 1997 (62 FR 66633), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0168. The approval expires on April 30, 2001.

Dated: April 16, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–10781 Filed 4–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0046]

Comprehensive List of Current Guidance Documents at the Food and Drug Administration; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a document that published in the **Federal Register** of February 26, 1998 (63 FR 9795). The document provided a comprehensive list of all guidance documents currently in use at the agency. FDA committed to publishing this list in its February 1997 ''Good Guidance Practices'' (GGP's), which set forth the agency policies and procedures for the development, issuance, and use of guidance documents. The document was published with several errors. This document corrects those errors.

DATES: General comments on this list and on agency guidance documents are welcome at any time.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Lisa L. Barclay, Office of Policy (HF–22), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3360.

In FR Doc. 98–4916, appearing on page 9795, in the **Federal Register** of Thursday, February 26, 1998, the following corrections are made:

1. On page 9795, in the second column, under the ''ADDRESSES'' caption, ''(HFD–305)'' is removed and ''(HFA–305)'' is added in its place.

2. On page 9834, in the fifth entry entitled ''Clinical Testing of Infant Formulas with Respect to Nutritional Suitability for Term Infants,'' in the second column, ''1985'' is removed and ''1988'' is added in its place.

3. On page 9834, in the first column, the sixth entry entitled ''Guidelines for the Evaluation of the Safety and Suitability of New Infant Formulas for Feeding Infants with Allergic Diseases'' is removed and ''Evaluation of Safety and Suitability of New Infant Formulas for Feeding Preterm Infants'' is added in its place.

4. On page 9834, under the heading, ''VI. Guidance Documents Issued by the Center for Veterinary Medicine (CVM),''